Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday.
Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity. The pharmaceutical company said Thursday that it has also signed a deal with Flagship-founded startup Cellarity to develop a new medicine for the fatty liver disease MASH, formerly known as NASH.
These are the first two deals announced under a collaboration agreement Flagship and Novo Nordisk struck in 2022.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.statnews.com/2024/01/04/novo-nordisk-enlists-two-flagship-biotechs-to-develop-obesity-mash-drugs/?utm_campaign=rss